Stonepine Capital Management, LLC
Position in ZNTL — Zentalis Pharmaceuticals, Inc.
CIK 1440771
BEND, OR
Position in ZNTL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$629,694
+$3,699 QoQ
Shares Held
269,100
-42.0% QoQ
Ownership
0.378%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZNTL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Stonepine Capital Management, LLC holds $317,990,358 across 56 Biotechnology names. ZNTL ranks #29 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RADX |
Radiopharm Theranostics Ltd
|
51,000,000 | $219,300,000 | |
| 2 | VSTM |
Verastem, Inc.
|
3,302,300 | $17,502,190 | |
| 3 | TENX |
Tenax Therapeutics, Inc.
|
975,200 | $15,593,448 | |
| 4 | ADMA |
Adma Biologics, Inc.
|
740,000 | $6,667,400 | |
| 5 | CAMP |
Camp4 Therapeutics Corp
|
1,389,622 | $6,128,233 | |
| 6 | NKTR |
Nektar Therapeutics
|
85,000 | $6,115,750 | |
| 7 | ZVRA |
Zevra Therapeutics, Inc.
|
480,000 | $4,473,600 | |
| 8 | CRBP |
Corbus Pharmaceuticals Holdings, Inc.
|
383,462 | $3,600,708 |
All Filings in ZNTL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $629,694 | 269,100 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $625,995 | 463,700 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $685,238 | 453,800 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $126,451 | 109,010 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $95,400 | 60,000 | Shares | Sole | 2025-05-14 | |
| No filing history on record for this holder in this stock. | ||||||